No way they will split the stock after buying back $5b in shares. But I do see this stock hitting $500 in about a year or so.
I think the decline in starter kits is because they have already heavily saturated the MS market. Starter kits would be for new patients which they are running out of because 1. they already have a ton of patients already on drug and 2. patients not on Tec are stable on their current medication. The MS market is not that big in the US with about 400,000 patients diagnosed with MS. Growth was bound to slow at some point. And while I agree that the tolerability issues are real, I don't think that is the reason for the decline. Most providers are able to titrate and get patients through the tolerability issues in the beginning of treatment.
My opinion is that Tec has so heavily saturated the MS market in such a short time, it was only a matter of time before growth began to slow. Remember Mike, their are only roughly 400,000 patients in the US with MS. They are running out of appropriate patients to put on Tec and that is why I think the numbers are starting to slow. Patients that are not on Tec at this point are on a competitor and stable. Providers won't dare switching a stable patient with MS.
Yes that was me. While I agree that some patients have had tolerability issues with Tec, I don't think providers incorrectly prescribed it. It was the hot new oral drug that had pretty good data and might have the possibility of being neuroprotective, that's what drove a lot of prescribers to use it. Some providers were better able to titrate patients up to help mitigate the tolerability issues and keep them on it long term.
Yeah Mike I saw you responded to my comment about BIIB but I can't read your response because it says post was deleted. Weird huh?
Mike, you are comparing apples to oranges. Patients don't switch from Tecfidera to Acthar, so you can't assume if Tec's numbers are down and Acthar's are up, that patients switched. Tecfidera is a DMT, Acthar is only used for acute relapses. Acthar is only used short term in conjunction with a DMT to help patients recover faster from an MS relapse. Get it?
Bokka, stop hittin the crack pipe and do some research!!
Fraud stock?? Earnings were great, just not the crazy forecast WS wanted. Tecfidera can not keep growing at the rate WS wants. The market isn't big enough for that to continue but it will take up a large market share of all MS business.